Every ingredient in Rebound Vitamins is selected for a specific, documented role in alcohol withdrawal recovery. Here is the clinical and scientific rationale behind each one.
Alcohol use disorder creates a predictable, severe pattern of micronutrient depletion. Ethanol impairs absorption, accelerates excretion, and displaces nutrient-dense food — leaving patients entering withdrawal with deficits that directly worsen seizure risk, neurological injury, and recovery outcomes.
Rebound Vitamins was formulated to address this pattern comprehensively — not just the three nutrients most protocols require, but the full spectrum of deficiencies documented in the peer-reviewed literature.
Thiamine deficiency is present in up to 80% of patients with alcohol use disorder. Ethanol blocks thiamine absorption at the intestinal level and impairs hepatic storage. Without adequate thiamine, pyruvate cannot enter the Krebs cycle — neurons starve of ATP, producing the classic triad of Wernicke's encephalopathy: ophthalmoplegia, ataxia, and confusion. The 100 mg oral dose in Rebound matches the standard prophylactic dose recommended by ASAM and UCSF CIWA-Ar guidelines.
Thiamine pyrophosphate (TPP) is the active coenzyme for pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and transketolase — all critical for neuronal energy metabolism and the pentose phosphate pathway.
Chronic alcohol use impairs folate absorption in the jejunum and increases urinary folate excretion two- to threefold. Folate deficiency is the most common vitamin deficiency in patients with AUD, contributing to macrocytic anemia, hyperhomocysteinemia, and neurological dysfunction. The 0.4 mg dose provides daily repletion consistent with standard supplementation guidelines.
Folate is essential for one-carbon metabolism, DNA synthesis, and the methylation cycle. Deficiency elevates homocysteine — an independent neurotoxin — and impairs myelin synthesis and repair.
Hypomagnesemia is present in 30–80% of patients with AUD and is directly linked to lowered seizure threshold during withdrawal. Alcohol increases renal magnesium wasting and reduces intestinal absorption. Oral magnesium supplementation supports benzodiazepine efficacy by stabilizing NMDA receptor activity and reducing neuromuscular excitability throughout the withdrawal period.
Magnesium acts as a physiological NMDA receptor antagonist. During alcohol withdrawal, NMDA receptors are upregulated — magnesium deficiency removes a key brake on excitatory neurotransmission, increasing seizure and delirium risk.
Patients with AUD are broadly malnourished across the entire B-vitamin spectrum. Riboflavin (B2) deficiency causes peripheral neuropathy and mucositis. Niacin (B3) deficiency produces pellagra-like symptoms. Pyridoxine (B6) deficiency impairs GABA synthesis — directly relevant to withdrawal severity. B12 deficiency contributes to megaloblastic anemia and subacute combined degeneration of the spinal cord. Rebound addresses all of these with a complete B-complex rather than isolated supplementation.
B vitamins serve as coenzymes across the citric acid cycle, electron transport chain, and neurotransmitter synthesis pathways. B6 is the direct precursor to pyridoxal phosphate, the coenzyme for glutamate decarboxylase — the enzyme that synthesizes GABA from glutamate.
Chronic alcohol consumption generates reactive oxygen species (ROS) that deplete ascorbic acid stores. Oxidative stress during withdrawal contributes to hepatocellular injury, neuroinflammation, and impaired immune function. Vitamin C supplementation supports glutathione recycling and collagen synthesis during the recovery period.
Ascorbic acid is a direct free-radical scavenger and a cofactor for dopamine β-hydroxylase — the enzyme that converts dopamine to norepinephrine. It also regenerates vitamin E from its oxidized form, amplifying antioxidant capacity.
Vitamin D deficiency is highly prevalent in patients with AUD due to reduced sun exposure, impaired hepatic 25-hydroxylation, and poor dietary intake. Deficiency is associated with increased fracture risk, impaired immune function, and depression — all relevant to the withdrawal and early recovery period.
Vitamin D3 (cholecalciferol) is converted to 25(OH)D in the liver and then to the active 1,25(OH)2D in the kidney. The active form binds nuclear vitamin D receptors in over 200 cell types, regulating calcium homeostasis, immune modulation, and neurotrophic factor expression.
Alcohol-induced oxidative stress depletes fat-soluble antioxidants including vitamin E. Tocopherol protects neuronal and hepatic cell membranes from lipid peroxidation — a key mechanism of alcohol-related organ damage. Supplementation supports membrane integrity during the acute withdrawal and recovery phase.
Alpha-tocopherol intercepts lipid peroxyl radicals in cell membranes, terminating chain reactions that would otherwise destroy polyunsaturated fatty acids. It works synergistically with vitamin C, which regenerates oxidized tocopherol.
Zinc deficiency is common in AUD due to reduced dietary intake, impaired intestinal absorption, and increased urinary zinc excretion. Zinc is required for over 300 enzymatic reactions and is critical for immune function, wound healing, and taste/smell perception — all impaired in patients with AUD. Zinc also plays a role in modulating NMDA receptor activity, relevant to withdrawal neurotoxicity.
Zinc is a structural component of zinc-finger proteins, a cofactor for alcohol dehydrogenase (the primary enzyme of ethanol metabolism), and an allosteric modulator of NMDA and GABA-A receptors — making it directly relevant to the neurochemistry of withdrawal.
Rather than requiring clinicians to order four separate supplements — thiamine, folic acid, magnesium, and a multivitamin — Rebound consolidates the complete evidence-based nutritional protocol into a single tablet taken twice daily during active withdrawal, then once daily through six weeks of recovery.
A complete reference for ED providers treating alcohol intoxication, withdrawal, and AUD — covering diagnostic codes, treatment procedures, SBIRT screening, and discharge documentation to support maximum insurance reimbursement.
Estimated reimbursement range per ED encounter for alcohol-related presentation, depending on complexity level, procedures performed, and payer mix. Proper code selection and SBIRT documentation are the primary levers.
* Rates are illustrative estimates. Actual reimbursement varies by payer, state, and contract. Verify with your billing department.
Proper discharge documentation is the single most important factor in recouping full reimbursement for an alcohol-related ED encounter. The following elements should be present in every discharge summary.
Record the initial CIWA-Ar score and any repeat scores during the visit. The score directly supports E&M level selection (99283 vs. 99284 vs. 99285) and justifies benzodiazepine administration. A score ≥ 10 supports moderate complexity; ≥ 15 supports high complexity.
Document the quantitative serum ethanol level (CPT 82055). The BAL at presentation supports the primary ICD-10 diagnosis code selection and establishes medical necessity for monitoring and IV fluids.
Document IV or IM thiamine administration (J3490) with dose and route. Note any signs of Wernicke's encephalopathy (E51.2). Thiamine must be given before glucose in suspected deficiency — document the sequence.
Document serum magnesium (CPT 83735) and any IV magnesium sulfate administered (J3475 per 500 mg). Hypomagnesemia (E61.2) as a secondary diagnosis supports the administration and the supplementation recommendation at discharge.
Document the screening tool used (AUDIT, AUDIT-C, DAST-10), the score, and the brief intervention provided. This is required to bill 99408/99409 or G0396/G0397. The intervention must be face-to-face and documented as a separate service.
List all medications prescribed or recommended at discharge, including oral thiamine, folate, magnesium, and Rebound Vitamins. Documenting a structured nutritional supplementation plan supports the medical necessity narrative for the encounter and any follow-up claims.
Document referrals to outpatient AUD treatment, MAT programs, or primary care. A documented referral supports the SBIRT billing codes and demonstrates care coordination — a factor in value-based reimbursement models and readmission reduction programs.
The principal diagnosis drives DRG assignment for inpatient admissions and APC assignment for outpatient ED visits. Sequence the most resource-intensive condition first (e.g., F10.231 for DTs rather than F10.120 for uncomplicated intoxication) to capture the correct payment weight.
SBIRT codes G0396/G0397 are covered under Medicare Part B when billed by a physician, NP, or PA. The service must be face-to-face and documented as a distinct service from the E&M visit. Use modifier -25 on the E&M code to indicate a separately identifiable service.
Coverage for SBIRT (H0049/H0050) varies by state plan. Most states cover at least one SBIRT screening per year. Brief intervention units (H0050) are billed per 15 minutes. Verify your state's specific billing rules and any prior authorization requirements.
Most commercial plans cover SBIRT under preventive services (ACA §2713) with no cost-sharing when billed with a Z-code secondary diagnosis (Z13.89 — encounter for screening for other disorder). Confirm payer-specific coding requirements.
For uninsured patients, document the full encounter as if billing insurance. This creates a complete medical record that supports any future coverage determination, Medicaid retroactive eligibility, or charity care application.
Review the full CIWA-Ar integration guide or order for your practice today.
Medical Disclaimer: This page is intended as a clinical reference for licensed healthcare providers. Rebound Vitamins is a nutritional supplement, not a pharmaceutical product, and does not replace clinical judgment or institutional protocol. IV Thiamine and IV Magnesium remain indicated when clinically required regardless of oral supplementation. Billing code descriptions and estimated rates are provided for reference only and do not constitute billing advice. Actual reimbursement varies by payer, state, and contract. Always verify codes with your compliance officer, billing department, or payer. These statements have not been evaluated by the Food and Drug Administration. — Wallace Peoples, C.E.O., W.Peoples Pharmaceuticals